Lonza Plans API Joint Venture in South Africa

Lonza says it is in discussions with the South African government for establishing a joint venture called Ketlaphela to build an active pharmaceutical ingredient (API) manufacturing facility for anti-retroviral medicines in South Africa. The discussions are at an early stage and no deal has been signed yet, Lonza says. The jv facility will involve a total investment of about rand1.6 billion ($208 million), which will include a rand500 million investment by Lonza, local press reports say. Construction of the plant is expected to begin next year, and the plant is...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers